



One Evertrust Plaza, Suite 1207
Jersey City, NJ, 07302
Phone: 201-401-1104
Email: celltrionusa@celltrion.com

May 4, 2023

**NOTIFICATION PURSUANT TO
18 V.S.A. § 4637(b)**

Subject: New prescription drug report

To: The Office of the Attorney General of Vermont

Celltrion USA, Inc. hereby notifies the Attorney General of Vermont of the following new prescription drug report pursuant to 18 V.S.A. § 4637(b).

Name of New Prescription Drug	NDC Number	Date of Commercial Availability	Wholesale Acquisition Cost as of the date of Commercial Availability
Vegzelma bevacizumab-adcd INTRAVENOUS 4 ml	72606-0011-01	4/10/2023	\$677.40
Vegzelma bevacizumab-adcd INTRAVENOUS 16 ml	72606-0012-01	4/10/2023	\$2709.60

Breakthrough Therapy/Priority Review/ Acquisition Date:

Vegzelma was developed by Celltrion and was not acquired, and was not granted breakthrough therapy designation or priority review by the FDA prior to final approval.

Marketing Plan Description:

Vegzelma will be launched in the U.S. for appropriate and eligible patients treated at oncology clinics and hospitals. All marketing, sales, and promotional activities messages will be limited to the approved product label data and information.

Estimated Number of Patients:

2,235

Please let us know if any additional information is required.

Sincerely,

JoonHwan Bae

Chief Operating Officer
Celltrion USA, Inc.